KAILERA Therapeutics Stock
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. The company emphasizes innovative approaches, including injectable and oral formulations, to support chronic weight management. Its lead program is a dual-action gut hormone receptor agonist that has demonstrated promising clinical results in early trials. By advancing these therapies, Kailera seeks to offer patients effective treatment options that enhance health and quality of life.
Sign up for SecondMarket® to view the market and buy or sell KAILERA Therapeutics Stock
Buy + SellKAILERA Therapeutics Funding
Sign up to gain insights into KAILERA Therapeutics funding history, including the funding round, time period, and amount raised.
Sign Up to Unlock the Data| Financing Round | Date | Amount | Price per share* | Valuation* |
|---|---|---|---|---|
| Series A | Oct 01, 2024 | 356.78M |
See KAILERA Therapeutics Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into KAILERA Therapeutics Stock Valuation + Share Prices
View real-time Tape D® data on KAILERA Therapeutics stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket trading platform.
Get Started
KAILERA Therapeutics Management Team
-
CEO, President, Board Member
Ron Renaud
-
COO, Chief Business Officer
Paul Burgess
-
Board Member
John F. Milligan
-
Board Member
Andrew Kaplan
-
Chief Medical Officer
Scott Wasserman
-
Chief Legal Officer
Scott Akamine
-
Board Member
Michael Gladstone
-
Board Member
Adam Koppel
-
Board Member
Christopher Hite
-
Board Member
Amir Zamani
-
CTO
Doug Bakan
-
Chief Commercial Officer
Jamie Coleman
-
Chief People Officer
Paula Cloghessy
KAILERA Therapeutics Major Investors
-
Atlas Venture Advisors
-
Lyra Capital
-
Royalty Pharma
-
RTW Investments
-
Invus Financial Advisors
-
Adage Capital Management
-
CPP Investments
-
Janus Henderson
-
Qatar Investment Authority (QIA)
-
Bain Capital Ventures
Learn More About KAILERA Therapeutics Stock
Buy KAILERA Therapeutics Stock
01KAILERA Therapeutics stock does not trade on public stock exchanges. KAILERA Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in KAILERA Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Sell KAILERA Therapeutics Stock
02KAILERA Therapeutics Stock does not trade on public stock exchanges. In order to sell KAILERA Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
KAILERA Therapeutics Stock Price
03KAILERA Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the Tape D™ database from Nasdaq Private Market, you can view KAILERA Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
KAILERA Therapeutics Stock Ticker Symbol
04There is no ticker symbol for KAILERA Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Criteria to Sell KAILERA Therapeutics Stock
05Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell KAILERA Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Criteria to Buy or Invest in KAILERA Therapeutics Stock
06Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in KAILERA Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
KAILERA Therapeutics Stock Settlement
07Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
KAILERA Therapeutics IPO
08KAILERA Therapeutics is a private company and has not had an IPO. There is currently no KAILERA Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Tape D™ database and gain access to actionable data related to KAILERA Therapeutics IPO.
Learn more about Tape D™ private company stock data for institutional investors on the on the Tape D™ Product Page.
Sign up for SecondMarket® to view the market and buy or sell KAILERA Therapeutics Stock
Buy + Sell*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.
